Cargando…

Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield(TM)®) and BBV-152 (Covaxin(TM)®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study

BACKGROUND: We assessed the humoral immune response of both ChAdOx1-nCOV (Covishield(TM)) and BBV-152 (Covaxin(TM)) vaccines in Indian health care workers (HCW). METHODS: A Pan-India, Cross-sectional, Coronavirus Vaccine-induced Antibody Titre (COVAT) study was conducted that measured SARS-CoV-2 ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Awadhesh Kumar, Phatak, Sanjeev Ratnakar, Singh, Ritu, Bhattacharjee, Kingshuk, Singh, Nagendra Kumar, Gupta, Arvind, Sharma, Arvind
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461292/ https://www.ncbi.nlm.nih.gov/pubmed/34600747 http://dx.doi.org/10.1016/j.vaccine.2021.09.055

Ejemplares similares

Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Pityriasis Rosea Following Covaxin (BBV152) Vaccination for COVID-19
por: Singh, Bhabani S. T. P., et al.
Publicado: (2022)

Inactivated vaccine Covaxin/BBV152: A systematic review
por: Ahmed, Tousief Irshad, et al.
Publicado: (2022)

Effectiveness of Covid-19 vaccines (Covishield(TM) and Covaxin (®)) in healthcare workers in Mumbai, India: A retrospective cohort analysis
por: Contractor, Aashish, et al.
Publicado: (2022)

Clinical outcomes in individuals hospitalized with SARS-CoV-2 Delta variant (B.1.617.2) who had been vaccinated with Covishield (ChAdOx1) and Covaxin (BBV-152)
por: Munigela, Apoorva, et al.
Publicado: (2022)

Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELD(TM) and COVAXIN(®) induced immunity in COVID-19 exposed Indians
por: Rakshit, Srabanti, et al.
Publicado: (2023)

Prime-Boost Vaccination With Covaxin/BBV152 Induces Heightened Systemic Cytokine and Chemokine Responses
por: Kumar, Nathella Pavan, et al.
Publicado: (2021)

Nephrotic Syndrome with Acute Kidney Injury after Covaxin (BBV152) COVID-19 Vaccination: A Case from India
por: Patel, Prem S., et al.
Publicado: (2023)

Psoriasis Flare-Up After COVAXIN BBV152 Whole Virion Inactivated Vaccine
por: Infimate, DJ L, et al.
Publicado: (2022)

Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study
por: Rose, Winsley, et al.
Publicado: (2023)

Anti SARS-CoV 2 IgG antibody response in fully vaccinated Covishield (AZD1222) and Covaxin (BBV-152) recipients: a study done in southern part of West Bengal, India
por: Satpathi, Partha Sarathi, et al.
Publicado: (2022)

Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELD™ or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center
por: Prasad, Narayan, et al.
Publicado: (2022)

Humoral Immune Response to BBV152 (Covaxin) SARS-CoV-2 Vaccine in Patients on Hemodialysis
por: Vijayaraghavan, Radha, et al.
Publicado: (2023)

Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study
por: Bhatnagar, Tarun, et al.
Publicado: (2022)

“Covishield and Covaxin” – India's contribution to global COVID-19 pandemic
por: Raina, Sunil Kumar, et al.
Publicado: (2021)

Pre-existing antibody levels negatively correlate with antibody titers after a single dose of BBV152 vaccination
por: Das, Suman, et al.
Publicado: (2022)

Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review
por: Das, Swarnali, et al.
Publicado: (2022)

Two Cases of Double-Positive Antineutrophil Cytoplasmic Autoantibody and Antiglomerular Basement Membrane Disease After BBV152/Covaxin Vaccination
por: Prema, Jansi, et al.
Publicado: (2021)

A machine learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys
por: Singh, Prateek, et al.
Publicado: (2022)

Adverse effects after first and second dose of covishield and covaxin: A longitudinal study
por: Mittal, Amit, et al.
Publicado: (2022)

Estimation of SARS-CoV-2 IgG Antibodies in Healthcare Worker-Administered Covishield and Covaxin Vaccines at a Tertiary Care Hospital in Jharkhand, India
por: Singh, Bishnupati, et al.
Publicado: (2023)

Myoglobinuria-induced Acute Kidney Injury Secondary to Covishield(TM) Vaccination
por: Fatima, Rana, et al.
Publicado: (2022)

Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)
por: Sunagar, Raju, et al.
Publicado: (2022)

Comparison of in-hospital COVID-19 related outcomes between COVISHIELD and COVAXIN recipients
por: Suri, Tejas M., et al.
Publicado: (2022)

Durability of ChAdOx1 nCoV-19 (Covishield(®)) Vaccine Induced Antibody Response in Health Care Workers
por: Verma, Alka, et al.
Publicado: (2022)

Bbv-152: Subacute thyroiditis: case report
Publicado: (2022)

BBV-152: Myocarditis and myositis: case report
Publicado: (2022)

BBV-152: Herpes zoster: case report
Publicado: (2022)

BBV-152: Reactivation of uveitis : case report
Publicado: (2022)

Clinical profile of ChAdOx1 nCoV-19- and BBV152-vaccinated individuals among hospitalized COVID-19 patients: a pair-matched study
por: Keri, Vishakh C., et al.
Publicado: (2022)

Impact of prior vaccination with Covishield(TM) and Covaxin® on mortality among symptomatic COVID-19 patients during the second wave of the pandemic in South India during April and May 2021: a cohort study
por: Abhilash, Kundavaram Paul Prabhakar, et al.
Publicado: (2022)

Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study
por: Singh, Amandeep, et al.
Publicado: (2022)

Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study
por: Kumar, Nathella Pavan, et al.
Publicado: (2021)

Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Covishield(TM)) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021
por: Murali, Sharan, et al.
Publicado: (2022)

Persistence of Antibodies Against Spike Glycoprotein of SARS-CoV-2 in Healthcare Workers Post Double Dose of BBV-152 and AZD1222 Vaccines
por: Choudhary, Hari Ram, et al.
Publicado: (2021)

BBV-152: Cutaneous small vessel vasculitis: case report
Publicado: (2021)

Bbv-152: Cutaneous small-vessel vasculitis: case report
Publicado: (2021)

2371. A study to describe the pattern of cutaneous adverse effects of COVID-19 vaccines (Covishield and Covaxin )
por: Mitra, Debdeep, et al.
Publicado: (2023)

Single-dose of BBV-152 and AZD1222 increases antibodies against spike glycoprotein among healthcare workers recovered from SARS-CoV-2 infection
por: Parai, Debaprasad, et al.
Publicado: (2021)

Azd-1222/bbv-152: Diabetic ketoacidosis: 2 case reports
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_65378g39071beolltn2e0gs9pv